Neutrophils as potential therapeutic targets in hepatocellular carcinoma

Volume: 19, Issue: 4, Pages: 257 - 273
Published: Jan 12, 2022
Abstract
The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer immunotherapeutic agents. Thus far, the principal focus of cancer immunotherapy has been on interrupting immune checkpoints that suppress antitumour lymphocytes. As well as lymphocytes, the HCC environment includes numerous other immune cell types, among which neutrophils...
Paper Details
Title
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Published Date
Jan 12, 2022
Volume
19
Issue
4
Pages
257 - 273
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.